AVE(SH:688067) Shang Hai Zheng Quan Bao·2025-11-11 19:27Core Viewpoint - Awei Technology Co., Ltd. has announced that its wholly-owned subsidiary, Hunan Awei Medical Testing Co., Ltd., has obtained a medical institution practice license, allowing it to provide third-party medical testing services, which is expected to create a new growth point for the company [1][2]. Group 1: License Acquisition - Hunan Awei Medical Testing Co., Ltd. received the medical institution practice license from the Health and Health Bureau of Hunan Xiangjiang New District [1]. - The license is valid from November 4, 2025, to November 3, 2030, and covers various diagnostic specialties including clinical microbiology and clinical chemistry [1]. Group 2: Impact on Business - The acquisition of the license enables the company to integrate its existing testing instruments and reagents with testing services, promoting a "device + service" business model [2]. - The impact on the company's performance post-launch of the testing laboratory remains uncertain due to factors such as industry supply and demand, market competition, and brand promotion [2]. Group 3: Investor Communication - The company will hold a third-quarter performance briefing on November 24, 2025, to discuss its operational results and financial status, allowing investors to engage in Q&A [6][7]. - Investors can submit questions from November 17 to November 21, 2025, through the Shanghai Stock Exchange Roadshow Center [8].